2026-04-20
Takeda presents additional Phase 3 clinical insights on investigational TYK2 inhibitor zasocitinib (TAK-279) at AAD 2026
2026-01-22
Zasocitinib (TAK-279) meets primary and secondary endpoints in Phase 3 plaque psoriasis studies